Stockreport

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]

Edgewise Therapeutics, Inc.  (EWTX) 
PDF – Announced positive top-line results from Phase 2 CANYON trial of sevasemten in Becker – – On track to report data from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hyper [Read more]